Stephanie L. Graff, MD, provides an overview of ESR1 mutations in ER+/HER2- metastatic breast cancer, highlighting their prevalence, clinical implications, and challenges.
Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.